Previous Close | 111.71 |
1-Year Change | 95.54% |
6-Months Change | 29.8% |
3-Months Change | 7.84% |
Moving Avg (50d) | 107.17 |
Moving Avg (200d) | 90.38 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.95B |
Beta (3-Years) | 1.09 |
Revenue Growth (ttm) | -24.06% |
Net Profit Margin (ttm) | 10.73% |
Return On Assets (ttm) | 2.14% |
EPS (ttm) | 0.82 |
PE Ratio (ttm) | 136.23 |
Dividend Yield | % |
Asset Description: | Ligand Pharmaceuticals Incorporated |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-11-04 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
116.806 | 113.231 | 110.847 | 107.271 | 101.312 | 95.352 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.